Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials - Schadendorf, D; Wolchok, J D; Hodi, F S (J Clin Oncol, 2017)
et al.